Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Gastric Adenocarcinoma Clinical Trial

Official title:

PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02366819
• Other study ID #: IRB14-0594
• Secondary ID: NCI-2014-02574IR
• Status: Recruiting
• Phase: Phase 4
• Start date: December 11, 2014
• Est. completion date: June 8, 2025

Study information

• Verified date: April 2024
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin calcium may also help fluorouracil work better. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.

Description:

PRIMARY OBJECTIVES:

I. To determine the residual tumor (R) 0 resection rate. II. To determine the pathologic complete response (pCR) rate of up to 36 patients treated with 4 cycles of neoadjuvant mFOLFIRINOX (UGTA1A1 genotype-dosed irinotecan [irinotecan hydrochloride]) regimen.

SECONDARY OBJECTIVES:

I. Response rate (radiographic [computed tomography (CT)], and metabolic (positron emission tomography [PET] maximum standardized uptake value [SUVmax]) to chemotherapy.

II. Chemotherapy-related toxicity. III. Surgical morbidity. IV. Overall survival (OS) measured from the time of histologic diagnosis. V. Disease-free survival measured from the time of histologic diagnosis. VI. Pattern of recurrence (distant, locoregional, both). VII. Human epidermal growth factor receptor 2 positive (HER2+) vs HER2 negative (-) difference in clinical outcomes.

OUTLINE:

PREOPERATIVE THERAPY: Patients receive oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

SURGERY: Patients undergo surgery.

POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: June 8, 2025
• Est. primary completion date: June 8, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed locally advanced gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral) adenocarcinomas are eligible for enrolment but will not be included in the primary analysis

• Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)

• All patients must have diagnostic laparoscopy with diagnostic washings for cytology; both cytology positive and negative patients are eligible for enrolment, but only cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible

• Eastern Cooperative Oncology Group (ECOG) performance status =< 1

• Eligible for surgery with curative intent

• Absolute neutrophil count (ANC) >= 1250/ul

• Hemoglobin >= 9 g/dL

• Platelets >= 100,000/ul

• Total bilirubin < 1.5 x upper limit of normal

• Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver metastases

• Creatinine =< 1.5 x upper limit of normal

• Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 will be allowed

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately

• Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan

• Signed informed consent

Exclusion Criteria:

• Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%

• Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's disease, ulcerative colitis)

• Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)

• Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0

• Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment

• Active uncontrolled bleeding

• Pregnancy or breastfeeding

• Major surgery within 4 weeks

• Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be allowed and treated as in the *28/*28 dosing group

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Adenocarcinoma
• Esophageal Neoplasms
• Gastric Adenocarcinoma
• Stage IIB Gastric Cancer
• Stage IIIA Esophageal Adenocarcinoma
• Stage IIIA Gastric Cancer
• Stage IIIB Esophageal Adenocarcinoma
• Stage IIIB Gastric Cancer
• Stage IIIC Esophageal Adenocarcinoma
• Stage IIIC Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Oxaliplatin
Given IV
• Leucovorin Calcium
Given IV
• Irinotecan Hydrochloride
Given IV
• Fluorouracil
Given IV

Procedure:
• Conventional Surgery
Undergo surgery

Locations

Country	Name	City	State
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	Kellogg Cancer Center - Evanston Hospital	Evanston	Illinois
United States	NorthShore University HealthSystem	Evanston	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Circulating tumor cell (CTC) numbers derived from portal and peripheral blood samples	Pearson or Spearman rank correlation coefficients will be calculated between CTC numbers derived from portal and peripheral blood samples.	Up to 5 years
Other	Change in SUVmax for PET/CT studies	Will be analyzed lesion-by-lesion using paired t-tests or Wilcoxon, signed rank tests.	Baseline to after 8 weeks of chemotherapy
Other	Change in SUVmax for the primary esophageal tumor	Will be correlated with clinical and histopathological response rates by logistic regression, and with progression-free and overall survival by Cox regression analysis.	Baseline to up to 5 years
Primary	R0 (analysis will be performed evaluating the R0 rate)	Intention-to-treat analysis will be performed, and patients with tumor progression during/after neoadjuvant chemotherapy that precludes surgery will be included as non-R0 resection. A subset analysis will be performed evaluating the R0 rate for those patients actually undergoing surgery.	During surgery
Secondary	Response rate	Will be evaluated by reporting event rates along with exact (binomial distribution-based) 95% confidence intervals.	Up to 5 years
Secondary	Surgical morbidity	Will be evaluated by reporting event rates along with exact (binomial distribution-based) 95% confidence intervals.	Up to 5 years
Secondary	Pattern of recurrence	Will be evaluated by reporting event rates along with exact (binomial distribution-based) 95% confidence intervals.	Up to 5 years
Secondary	Incidence of toxicity based on NCI-CTCAE v 4.0	Toxicities will be summarized by type, grade, and attribution.	Up to 5 years
Secondary	OS (estimated using the Kaplan-Meier procedure and compared in the subgroups of patients with and without pCR (grade 1a) using the log-rank test)	Will be estimated using the Kaplan-Meier procedure and compared in the subgroups of patients with and without pCR (grade 1a) using the log-rank test.	Time from enrollment/registration to the time of death, of any cause, assessed up to 5 years
Secondary	Progression free survival	Will be estimated using the Kaplan-Meier procedure and compared in the subgroups of patients with and without pCR (grade 1a) using the log-rank test.	Time from enrollment/registration to time of progression or death from any cause, assessed up to 5 years